U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106827) titled 'A Study of GV20-0251 in Advanced or Refractory Solid Tumors' on July 09.
Brief Summary: This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellular Carcinoma
Cholangiocarcinoma
Melanoma
NSCLC (Non-small Cell Lung Cancer)
Pancreatic Ductal Adenocarcinoma
HNSCC
Endometrial Cancer
Testicular Cancer
Intervention:
DRUG: GV20-0251
Increasing doses of GV...